SUbstition of PERioperative Albumin Deficiency Disorders (SUPERADD)
Primary Purpose
Hypoalbuminemia
Status
Completed
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
Human albumin
Sponsored by
About this trial
This is an interventional treatment trial for Hypoalbuminemia
Eligibility Criteria
Inclusion Criteria:
- age: 18 years or older
- written informed consent
- ASA state 3 and 4 OR
- elective high risk surgery (open aortic surgery, open leg revascularization, thrombectomy, oesophagectomy, pancreatic surgery, cystectomy, liver surgery, change of knee- or hip-prothesis, amputation)
Exclusion Criteria:
- emergency surgery
- severe liver cirrhosis (child pugh C)
- need for dialysis
- patients already included in SUPERADD
- patients with a legal representative
- contraindications for human albumin: hypersensitivity for human albumin or any substance included in the preparation
- pregnancy
- breastfeeding women
- ASA state 5
- BMI > 35 kg/m2
Sites / Locations
- Klinikum rechts der Isar Dept. of Anesthesiology
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Human albumin
Control
Arm Description
Substitution of human albumin until serum albumin >30g/l; dosage: (30 g/l - serum albumin [g/l] ) x 0,04 l/kg x body weight [kg] x 2
Standard clinical care
Outcomes
Primary Outcome Measures
Postoperative complications assessed with POMS- and graded with Clavien-Dindo-Score
Postoperative complications will be detected using the POMS score. The severity of the complications will be graded with the Clavien-Dindo-Score. A complication will be regarded as clinical relevant when it is graded Clavien-Dindo-Score 2 or higher on at least one of the four days examined.
Secondary Outcome Measures
Length of hospital stay
Length of stay in postoperative anaesthesia care unit
Length of stay in intensive care unit
Long term mortality (6 month)
Short term mortality (hospital mortality)
Acute kidney injury
Incidence according to AKIN score (at least AKIN 1)
Quality of Recovery 9 Score
Assessed preoperatively and on day 1 and 3 an 6 month after surgery
Amount of volume infused
Amount of infusion of ringer's acetate and gelafundin
Dosage of catecholamines
Intra- and postoperative dosage of catecholamines
Number of red packed cells transfused
Number of platelet concentrates transfused
Amount of coagulation factors infused
Amount of PPSB and fibrinogen
Intra- and postoperative Hypotension
Decrease of more than 30% compared to value before induction
Incidence of pulmonal venous congestion
Incidence of pulmonal venous congestion assessed using chest x-ray
Therapy with diuretics
New onset or extension of diuretic treatment
Efficacy of albumin treatment
Efficacy of albumin treatment in order to increase serum albumin and colloid osmotic pressure
Full Information
NCT ID
NCT03167645
First Posted
October 18, 2016
Last Updated
April 22, 2021
Sponsor
Technical University of Munich
1. Study Identification
Unique Protocol Identification Number
NCT03167645
Brief Title
SUbstition of PERioperative Albumin Deficiency Disorders
Acronym
SUPERADD
Official Title
Does Perioperative Substitution of Albumin Deficiency Reduce Postoperative Complications?
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
June 19, 2017 (Actual)
Primary Completion Date
December 21, 2019 (Actual)
Study Completion Date
April 21, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Technical University of Munich
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Aim of this study is to reduce postoperative complications (assessed by POMS-Score and graded by Clavien-Dindo-Score) by substitution of perioperative hypoalbuminaemia in high-risk patients or patients undergoing high risk surgery.
Detailed Description
Perioperative hypoalbuminaemia is a common condition in high risk surgery and in high risk patients. It is associated with increased morbidity and mortality. Although many studies investigated albumin substitution in critically ill patients there is still no clear recommendation for its use over any other colloid. Except for some smaller studies especially in the setting of cardiac surgery the effect of perioperative albumin substitution has not been studied yet.
This study is designed to investigate the effect of perioperative albumin substitution in high risk patients or patients undergoing high risk surgery on postoperative complications assessed by the POMS-Score and graded according to severity by the Clavien-Dindo-Score.
Patients eligible for the study are informed in detail during the pre-medication visit and written informed consent will be obtained. Additionally the Quality of Recovery 9 Score (QoR-9) will be determined. During induction of anesthesia blood is taken from every patient and the serum albumin level is determined. In case albumin is greater than 30 g/l albumin levels are controlled every 3 hours and one last time on admission to the postoperative anaesthesia care unit (PACU). Should the albumin level do not fall below 30 g/l over the whole period the patient is not randomized.
Patients with albumin ≤30g/l will be randomized using a web-based computer-generated randomization list into one of two groups:
Group human albumin (HA):
In this group hypoalbuminaemia is treated with infusion of human albumin until serum albumin is greater than 30g/l. To verify success of the therapy, serum albumin levels are controlled every 3 hours during surgery, on admission to the PACU and if necessary again in the PACU.
Group control:
In this group patients are treated according to standard clinical care. To compare the effect of albumin substitution serum albumin is measured every 3 hours from beginning of anesthesia until discharge from the PACU.
In both groups patients will be discharged from the PACU when the patient is rated fit for discharge by the attending anesthetist and albumin level is >30g/l in the HA group.
A blinded investigator assesses the patients postoperative complications. He visits the patient on day 3, 5, 8 and 15 after surgery and determines the POMS-score (see reference: Grocott MP). If a complication is detected the assessor grades the complication according to its severity with the Clavien-Dindo-Score (see reference: Clavien PA). Additionally serum albumin and creatinine levels will be determined in routine blood tests. The patients QoR-9, the Charlson Comorbidity Score, the Preoperative Score to Predict Postoperative Mortality (POSPOM) and other secondary outcome (see Outcome Measures section) parameters will be obtained.
6 Month after surgery the patient or next of kin will be contacted in order to determine 6-month mortality and the QoR-9 score.
Postulating an incidence of complications (graded Clavien-Dindo-Score 2 or higher) of 52% in group control and a reduced incidence of 38% in group HA results in a total number of 400 patients (chi-square-test, α = 0,048, power 80%). As the actual incidence is unknown but has a significant impact on the number needed per group, an interims analysis will be performed after 100 included patients. Is the difference of the incidence of postoperative complications between the two groups significant with an α < 0,002 the study will be finished. Otherwise, the sample size needed per group will be corrected assuming a relative risk reduction of 25% (52% vs. 38%), an α = 0,048, a two-tailed test and a power of 80%.
The blinded and independent interims analysis after 100 patients revealed a corrected sample size of 300 patients per group (total 600 patients).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoalbuminemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
600 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Human albumin
Arm Type
Experimental
Arm Description
Substitution of human albumin until serum albumin >30g/l; dosage: (30 g/l - serum albumin [g/l] ) x 0,04 l/kg x body weight [kg] x 2
Arm Title
Control
Arm Type
No Intervention
Arm Description
Standard clinical care
Intervention Type
Drug
Intervention Name(s)
Human albumin
Other Intervention Name(s)
Human-Albumin 20 % Behring, salzarm
Intervention Description
Substitution according to pre-specified dosage
Primary Outcome Measure Information:
Title
Postoperative complications assessed with POMS- and graded with Clavien-Dindo-Score
Description
Postoperative complications will be detected using the POMS score. The severity of the complications will be graded with the Clavien-Dindo-Score. A complication will be regarded as clinical relevant when it is graded Clavien-Dindo-Score 2 or higher on at least one of the four days examined.
Time Frame
15 days
Secondary Outcome Measure Information:
Title
Length of hospital stay
Time Frame
until discharge from hospital, up to 6 month
Title
Length of stay in postoperative anaesthesia care unit
Time Frame
until discharge from postoperative anaesthesia care unit, up to 24 hours
Title
Length of stay in intensive care unit
Time Frame
until discharge from intensive care unit, up to 1 month
Title
Long term mortality (6 month)
Time Frame
6 month
Title
Short term mortality (hospital mortality)
Time Frame
until discharge from hospital, up to 6 month
Title
Acute kidney injury
Description
Incidence according to AKIN score (at least AKIN 1)
Time Frame
until discharge from hospital, up to 6 month
Title
Quality of Recovery 9 Score
Description
Assessed preoperatively and on day 1 and 3 an 6 month after surgery
Time Frame
6 month after surgery
Title
Amount of volume infused
Description
Amount of infusion of ringer's acetate and gelafundin
Time Frame
until discharge from postoperative anaesthesia care unit, up to 24 hours
Title
Dosage of catecholamines
Description
Intra- and postoperative dosage of catecholamines
Time Frame
until discharge from postoperative anaesthesia care unit, up to 24 hours
Title
Number of red packed cells transfused
Time Frame
until discharge from postoperative anaesthesia care unit, up to 24 hours
Title
Number of platelet concentrates transfused
Time Frame
until discharge from postoperative anaesthesia care unit, up to 24 hours
Title
Amount of coagulation factors infused
Description
Amount of PPSB and fibrinogen
Time Frame
until discharge from postoperative anaesthesia care unit, up to 24 hours
Title
Intra- and postoperative Hypotension
Description
Decrease of more than 30% compared to value before induction
Time Frame
until discharge from postoperative anaesthesia care unit, up to 24 hours
Title
Incidence of pulmonal venous congestion
Description
Incidence of pulmonal venous congestion assessed using chest x-ray
Time Frame
until discharge from postoperative anaesthesia care unit, up to 24 hours
Title
Therapy with diuretics
Description
New onset or extension of diuretic treatment
Time Frame
until discharge from hospital, up to 6 month
Title
Efficacy of albumin treatment
Description
Efficacy of albumin treatment in order to increase serum albumin and colloid osmotic pressure
Time Frame
until discharge from hospital, up to 6 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age: 18 years or older
written informed consent
ASA state 3 and 4 OR
elective high risk surgery (open aortic surgery, open leg revascularization, thrombectomy, oesophagectomy, pancreatic surgery, cystectomy, liver surgery, change of knee- or hip-prothesis, amputation)
Exclusion Criteria:
emergency surgery
severe liver cirrhosis (child pugh C)
need for dialysis
patients already included in SUPERADD
patients with a legal representative
contraindications for human albumin: hypersensitivity for human albumin or any substance included in the preparation
pregnancy
breastfeeding women
ASA state 5
BMI > 35 kg/m2
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manfred Blobner, MD
Organizational Affiliation
Klinikum rechts der Isar, Technical University Munich, Dept. of Anesthesiology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Klinikum rechts der Isar Dept. of Anesthesiology
City
Munich
ZIP/Postal Code
81675
Country
Germany
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
1598671
Citation
Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992 May;111(5):518-26.
Results Reference
background
PubMed Identifier
17689808
Citation
Grocott MP, Browne JP, Van der Meulen J, Matejowsky C, Mutch M, Hamilton MA, Levett DZ, Emberton M, Haddad FS, Mythen MG. The Postoperative Morbidity Survey was validated and used to describe morbidity after major surgery. J Clin Epidemiol. 2007 Sep;60(9):919-28. doi: 10.1016/j.jclinepi.2006.12.003. Epub 2007 May 7.
Results Reference
background
PubMed Identifier
32811539
Citation
Schaller SJ, Fuest K, Ulm B, Schmid S, Bubb C, von Eisenhart-Rothe R, Friess H, Kirchhoff C, Stadlbauer T, Luppa P, Blobner M, Jungwirth B. Substitution of perioperative albumin deficiency disorders (SuperAdd) in adults undergoing vascular, abdominal, trauma, or orthopedic surgery: protocol for a randomized controlled trial. Trials. 2020 Aug 18;21(1):726. doi: 10.1186/s13063-020-04626-2.
Results Reference
derived
Learn more about this trial
SUbstition of PERioperative Albumin Deficiency Disorders
We'll reach out to this number within 24 hrs